Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Swedish startup BioArctic Neuroscience CEO Pär Gellerfors wondered who was calling him at 8 a.m. one June morning back in 2003.
You may also be interested in...
Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost
Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.
Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost
Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.
Eisai Buys Alzheimer’s Disease Research Data From TorreyPines
TOKYO - Eisai said Nov. 11 it signed an agreement with California-based TorreyPines Therapeutics to purchase all research data and assets from TorreyPines' research activities on genes associated with late-onset Alzheimer's disease for an undisclosed upfront payment